Literature DB >> 20931669

In vitro antimicrobial susceptibility of Propionibacterium acnes isolated from acne patients in northern Mexico.

Roger González1, Oliverio Welsh, Jorge Ocampo, Rosa M Hinojosa-Robles, Lucio Vera-Cabrera, Mary L Delaney, Minerva Gómez.   

Abstract

BACKGROUND: Antimicrobials are essential in acne therapy. In the last decades, Propionibacterium acnes has become resistant to different antibiotics.
OBJECTIVE: To determine antimicrobial susceptibility patterns of P. acnes to frequently used drugs.
MATERIALS AND METHODS: Cutaneous lesion samples were obtained from 50 patients with acne vulgaris, which were cultured in anaerobic media to demonstrate the presence of P. acnes. After that, antimicrobial susceptibility tests to tetracycline, minocycline, doxycycline, erythromycin, azithromycin, clindamycin, trimethoprim/sulfamethoxazole (SXT) and levofloxacin were performed.
RESULTS: In the general study group, resistance to azithromycin was 82%, the most prevalent one (P < 0.05), followed by trimethoprim/sulfamethoxazole (68%) and erythromycin (46%). On the other hand, all strains isolated were susceptible to minocycline. Resistance bias were similar when subgroups with and without the previous antimicrobial therapy were performed, finding a low prevalence of resistance to tetracyclines and levofloxacin in both groups.
CONCLUSIONS: In our region, P. acnes is highly resistant to azithromycin, SXT, erythromycin and clindamycin; and being very susceptible to minocycline, levofloxacin and tetracycline, in vitro in both groups: with and without the previous antibiotic use. To our knowledge, high resistance prevalence to azithromycin and SXT has never been reported.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20931669     DOI: 10.1111/j.1365-4632.2010.04506.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  8 in total

Review 1.  Propionibacterium acnes: from commensal to opportunistic biofilm-associated implant pathogen.

Authors:  Yvonne Achermann; Ellie J C Goldstein; Tom Coenye; Mark E Shirtliff
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

2.  Antibiofilm effects of azithromycin and erythromycin on Porphyromonas gingivalis.

Authors:  H Maezono; Y Noiri; Y Asahi; M Yamaguchi; R Yamamoto; N Izutani; H Azakami; S Ebisu
Journal:  Antimicrob Agents Chemother       Date:  2011-09-12       Impact factor: 5.191

Review 3.  Acne, the Skin Microbiome, and Antibiotic Treatment.

Authors:  Haoxiang Xu; Huiying Li
Journal:  Am J Clin Dermatol       Date:  2019-06       Impact factor: 7.403

4.  Comparison effect of azithromycin gel 2% with clindamycin gel 1% in patients with acne.

Authors:  Fatemeh Mokhtari; Gita Faghihi; Akram Basiri; Sadaf Farhadi; Mohammadali Nilforoushzadeh; Shadi Behfar
Journal:  Adv Biomed Res       Date:  2016-04-19

5.  Propionibacterium acnes Susceptibility and Correlation with Hemolytic Phenotype.

Authors:  Travis E Wright; K Keely Boyle; Thomas R Duquin; John K Crane
Journal:  Infect Dis (Auckl)       Date:  2016-10-09

Review 6.  Potential Role of the Microbiome in Acne: A Comprehensive Review.

Authors:  Young Bok Lee; Eun Jung Byun; Hei Sung Kim
Journal:  J Clin Med       Date:  2019-07-07       Impact factor: 4.241

7.  Antibiotic Susceptibility of Cutibacterium acnes Strains Isolated from Israeli Acne Patients.

Authors:  Sivan Sheffer-Levi; Amit Rimon; Vanda Lerer; Tehila Shlomov; Shunit Coppenhagen-Glazer; Chani Rakov; Tamara Zeiter; Ran Nir-Paz; Ronen Hazan; Vered Molho-Pessach
Journal:  Acta Derm Venereol       Date:  2020-10-20       Impact factor: 3.875

8.  Cross-sectional Pilot Study of Antibiotic Resistance in Propionibacterium Acnes Strains in Indian Acne Patients Using 16S-RNA Polymerase Chain Reaction: A Comparison Among Treatment Modalities Including Antibiotics, Benzoyl Peroxide, and Isotretinoin.

Authors:  Kabir Sardana; Tanvi Gupta; Bipul Kumar; Hemant K Gautam; Vijay K Garg
Journal:  Indian J Dermatol       Date:  2016 Jan-Feb       Impact factor: 1.494

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.